Ron Bentsur Purchases 1,000 Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock
Nuvectis Pharma, Inc. (NASDAQ:NVCT – Get Rating) CEO Ron Bentsur acquired 1,000 shares of the stock in a transaction dated Friday, May 20th. The shares were bought at an average cost of $16.28 per share, with a total value of $16,280.00. Following the transaction, the chief executive officer now directly owns 2,962,614 shares of the company’s stock, valued at $48,231,355.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Ron Bentsur also recently made the following trade(s):
- On Wednesday, May 18th, Ron Bentsur acquired 1,700 shares of Nuvectis Pharma stock. The shares were bought at an average cost of $19.36 per share, with a total value of $32,912.00.
- On Monday, May 16th, Ron Bentsur bought 1,000 shares of Nuvectis Pharma stock. The shares were acquired at an average price of $19.32 per share, with a total value of $19,320.00.
- On Thursday, May 12th, Ron Bentsur bought 12,245 shares of Nuvectis Pharma stock. The shares were acquired at an average price of $16.99 per share, with a total value of $208,042.55.
- On Monday, March 28th, Ron Bentsur bought 4,000 shares of Nuvectis Pharma stock. The shares were acquired at an average price of $7.05 per share, with a total value of $28,200.00.
- On Thursday, March 17th, Ron Bentsur bought 7,000 shares of Nuvectis Pharma stock. The shares were acquired at an average price of $7.63 per share, with a total value of $53,410.00.
This is a stock chart pattern that signals a bullish market trend… Every investor should know this stock chart pattern.
There are two more on the next page.
Click here to see this pattern now
Shares of NVCT stock opened at $15.50 on Monday. The company has a fifty day moving average price of $10.77. Nuvectis Pharma, Inc. has a one year low of $3.08 and a one year high of $20.92.
Hedge funds have recently made changes to their positions in the business. Virtu Financial LLC bought a new position in shares of Nuvectis Pharma in the first quarter valued at about $84,000. BlackRock Inc. bought a new position in Nuvectis Pharma during the first quarter worth about $59,000. Finally, Ronit Capital LLP bought a new position in Nuvectis Pharma during the first quarter worth about $4,076,000.
NVCT has been the subject of several recent research reports. Roth Capital restated a “buy” rating on shares of Nuvectis Pharma in a report on Sunday, April 17th. HC Wainwright increased their price target on shares of Nuvectis Pharma from $14.00 to $21.00 in a research note on Tuesday, May 10th.
Nuvectis Pharma Company Profile (Get Rating)
Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $1,000 in Nuvectis Pharma right now?
Before you consider Nuvectis Pharma, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Nuvectis Pharma wasn’t on the list.
While Nuvectis Pharma currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
